Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
FOXO Technologies Inc. (FOXO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: FOXO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.47% | Avg. Invested days 9 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.99M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 3.25 | 52 Weeks Range 0.17 - 13.00 | Updated Date 06/28/2025 |
52 Weeks Range 0.17 - 13.00 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.25 |
Earnings Date
Report Date 2025-06-26 | When After Market | Estimate - | Actual -0.368 |
Profitability
Profit Margin -159.67% | Operating Margin (TTM) -48.8% |
Management Effectiveness
Return on Assets (TTM) -17.5% | Return on Equity (TTM) -1754.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11925576 | Price to Sales(TTM) 0.28 |
Enterprise Value 11925576 | Price to Sales(TTM) 0.28 | ||
Enterprise Value to Revenue 1.65 | Enterprise Value to EBITDA -0.33 | Shares Outstanding 10620600 | Shares Floating 6482011 |
Shares Outstanding 10620600 | Shares Floating 6482011 | ||
Percent Insiders 2.19 | Percent Institutions 0.47 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
FOXO Technologies Inc.
Company Overview
History and Background
FOXO Technologies Inc. was founded in 2021 and is a technology company focused on commercializing epigenetic technology to measure human biological age. It aims to provide insights for longevity and healthspan extension.
Core Business Areas
- Epigenetic Testing: Develops and offers epigenetic testing services that analyze DNA methylation patterns to determine an individual's biological age.
- Longevity Research: Conducts research and development efforts aimed at understanding the mechanisms of aging and identifying interventions that can promote healthy aging.
- Data Analytics: Uses bioinformatic tools and databases to analyze patterns and derive actionable insights from data obtained from epigenetic testing to improve human health
Leadership and Structure
Tyler Danielsson is the Chief Executive Officer. The organizational structure is typical of a tech startup, with departments focused on research, development, sales, and marketing.
Top Products and Market Share
Key Offerings
- FOXO Biosystems TrueAge Test: An epigenetic test measuring biological age. Competitors: Elysium Health Index, InsideTracker. While precise market share data is limited, FOXO is actively building its presence in the direct-to-consumer and wellness space.
- Reinsurance Products: Creates products and services that are related to life insurance and reinsurance industry. Competitors: SCOR, Munich RE, Reinsurance Group of America.
Market Dynamics
Industry Overview
The longevity and epigenetic testing market is rapidly growing, driven by increasing interest in personalized medicine and preventative healthcare. The industry is fragmented with many players vying for market share.
Positioning
FOXO is positioned as a technology leader in the epigenetic testing space, leveraging its proprietary technology to provide accurate and actionable insights into biological age. FOXO's competitive advantage lies in its focus on epigenetic testing and reinsurance product offerings.
Total Addressable Market (TAM)
The global longevity market is estimated to reach hundreds of billions of dollars. FOXO is well-positioned to capture a portion of this market with its epigenetic testing services and insurance products by establishing strategic partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary epigenetic technology
- Focus on reinsurance industry
- Experienced leadership team
- Early mover advantage in the longevity space
Weaknesses
- Limited brand recognition
- Relatively small revenue base
- High research and development costs
- Dependence on key personnel
Opportunities
- Growing demand for longevity solutions
- Potential partnerships with healthcare providers and insurers
- Expansion into new geographic markets
- Development of new epigenetic-based products
Threats
- Competition from larger, more established companies
- Regulatory hurdles
- Technological obsolescence
- Economic downturn impacting consumer spending on longevity products
Competitors and Market Share
Key Competitors
- Elysium Health (Privately Held)
- InsideTracker (Privately Held)
- SCOR SE (SCOR.PA)
- Munich RE (MUV2.DE)
- Reinsurance Group of America (RGA)
Competitive Landscape
FOXO faces competition from both established players in the longevity and life insurance spaces. It must differentiate itself through technological innovation, strategic partnerships, and effective marketing.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's short operating history. The stock experienced a major decline in the last year.
Future Projections: Future growth projections are dependent on the company's ability to commercialize its technology, secure partnerships, and expand its customer base. Analyst estimates are not available at this time. It is anticipated that the company is looking towards reinsurance to find growth.
Recent Initiatives: Recent initiatives include expanding the availability of its epigenetic tests and developing new applications for its technology.
Summary
FOXO Technologies Inc. is an emerging player in the longevity and epigenetic testing market with promising technology, but the company faces challenges with profitability and competition. FOXO's potential hinges on successful execution of its commercialization strategy and strategic partnerships to grow revenue in the epigenetic and life insurance product offering. The company must manage its high research and development costs and address concerns about its negative cash flow to achieve sustainable growth and long-term viability, requiring careful and comprehensive analysis.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Public Filings
- Industry Reports
- Market Data
- SEC Filings
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may not be complete or accurate. Investment decisions should be made based on your own due diligence and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About FOXO Technologies Inc.
Exchange NYSE MKT | Headquaters West Palm Beach, FL, United States | ||
IPO Launch date 2021-01-29 | CEO, Interim CFO, Interim Principal Accounting Officer & Director Mr. Seamus Lagan | ||
Sector Healthcare | Industry Health Information Services | Full time employees 102 | Website https://www.foxotechnologies.com |
Full time employees 102 | Website https://www.foxotechnologies.com | ||
FOXO Technologies Inc. operates as a healthcare services and technology company in the United States. The company operates through two segments: Healthcare and Labs and Life. The company offers behavioural health; ancillary, including laboratory, radiology, respiratory, and pharmacy; insurance; and other services. The company applies automated machine learning and artificial intelligence (AI) technologies to discover epigenetic biomarkers of human health, wellness, and aging. It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and Bioinformatics services that provides data solutions using AI and machine learning for data analysis and processing, and quality checking for academia, healthcare, government, and pharmaceutical research customers. FOXO Technologies Inc. was founded in 2020 and is based in West Palm Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.